申请人:Amarasinghe Kande Kankanamalage Dayarathna
公开号:US20110206609A1
公开(公告)日:2011-08-25
The present invention provides novel fluoroalkyl tetrabenazine carbinol compounds having structure I
wherein R
1
is a C
1
-C
10
fluorinated aliphatic radical; R
2
is a C
1
-C
10
aliphatic radical; R
3
is hydrogen or a C
1
-C
10
aliphatic radical; R
4
is hydrogen or a C
1
-C
10
aliphatic radical; and R
5
is hydrogen, a C
1
-C
10
aliphatic radical, a C
2
-C
10
cycloaliphatic radical, or a C
2
-C
20
aromatic radical. In a particular embodiment, —OR
5
is an ester moiety. The fluoroalkyl tetrabenazine carbinol compounds are provided in both racemic and enantiomerically enriched forms and may comprise either or both of fluorine-18 and fluorine 19. The fluoroalkyl tetrabenazine carbinol compounds are shown to possess high affinity for VMAT-2, a biomarker implicated in human diabetes. The fluoroalkyl tetrabenazine carbinol compounds comprising a fluorine-18 group are useful as PET imaging agents targeting the VMAT-2 biomarker. The non-radiolabled fluoroalkyl tetrabenazine carbinol compounds are useful as probes for the discovery of PET imaging agents.